Egle Therapeutics

We modulate regulatory T cells to rebalance immunity

Suresnes, France · Founded 2020 · $63.2M raised

Headquarters
Suresnes
Founded
2020
Total Funding
$63.2M
Last Round
$10.8M GrantMar 2025
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Founded in 2020 as a spin-off from Institut Curie in Paris, Egle Therapeutics is a clinical-stage biotech company developing precision immunotherapies that modulate regulatory T cells (Tregs) to rebalance immunity in cancer and autoimmune diseases. Its lead oncology program EGL-001 (an antagonist IL-2 mutein fused to a CTLA-4 antibody) is in Phase I trials, while EGL-003 for autoimmune disease entered Phase I in 2025.

Summary

Egle Therapeutics is a Biotech company based in Suresnes, France, founded in 2020. It has raised $63.2M in total across 2 rounds, most recently a $10.8M Grant round in Mar 2025. Investors include EQT AB.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantFrance 2030 State FundingMar 2025
$10.8M

Sign up to see all 2 events

Funding: Series A through Grant. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Egle Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/egle-therapeutics"><img src="https://indexed.vc/api/badge/company/egle-therapeutics" alt="Egle Therapeutics on Indexed.vc" width="260" height="76" /></a>